A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Nemunaitis, MD
Gradalis, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
- Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
- Henry Ford Hospital
Detroit, Michigan, United States
- Billings Clinic
Billings, Montana, United States
- Dartmouth-Hitchcock Medical Center/ Norris Cotton Cancer Center
Lebanon, New Hampshire, United States
- Prisma Health Cancer Institute
Greenville, South Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2017
- Primary completion
- 22 May 2019
- Completion
- 18 May 2022
- Last update posted
- 5 Apr 2023
- Registered enrollment
- 25
- Registry id
- NCT03073525
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.